Peter Bernhardt

5.3k total citations · 1 hit paper
130 papers, 3.8k citations indexed

About

Peter Bernhardt is a scholar working on Radiology, Nuclear Medicine and Imaging, Epidemiology and Oncology. According to data from OpenAlex, Peter Bernhardt has authored 130 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Radiology, Nuclear Medicine and Imaging, 56 papers in Epidemiology and 34 papers in Oncology. Recurrent topics in Peter Bernhardt's work include Radiopharmaceutical Chemistry and Applications (54 papers), Neuroendocrine Tumor Research Advances (54 papers) and Medical Imaging Techniques and Applications (40 papers). Peter Bernhardt is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (54 papers), Neuroendocrine Tumor Research Advances (54 papers) and Medical Imaging Techniques and Applications (40 papers). Peter Bernhardt collaborates with scholars based in Sweden, Switzerland and France. Peter Bernhardt's co-authors include Eva Forssell‐Aronsson, Håkan Ahlman, Lars Kölby, Ola Nilsson, Cristina Müller, Bo Wängberg, Roger Schibli, Johanna Svensson, Nicholas P. van der Meulen and Katarina Sjögreen Gleisner and has published in prestigious journals such as Cancer Research, Scientific Reports and Genetics.

In The Last Decade

Peter Bernhardt

126 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

2022 138 citations Katarina Sjögreen Gleisner, Nicolas Chouin et al. European Journal of Nuclear Medicine and Molecular Imaging profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Bernhardt Sweden	37	2.3k	1.3k	1.2k	931	688	130	3.8k
Francesco Scopinaro Italy	35	2.1k 0.9×	735 0.6×	874 0.8×	892 1.0×	383 0.6×	217	3.9k
Mark Konijnenberg Netherlands	41	3.8k 1.7×	1.8k 1.4×	1.8k 1.5×	1.5k 1.7×	886 1.3×	139	5.4k
Mahila Ferrari Italy	30	1.8k 0.8×	1.2k 0.9×	1.2k 1.0×	663 0.7×	703 1.0×	87	3.1k
Samer Ezziddin Germany	37	1.9k 0.8×	1.6k 1.2×	1.8k 1.6×	1.4k 1.5×	1.1k 1.6×	182	4.0k
Annibale Versari Italy	34	1.4k 0.6×	595 0.5×	990 0.9×	1.7k 1.8×	623 0.9×	162	4.2k
Alexander Haug Austria	42	2.0k 0.9×	1.6k 1.2×	1.8k 1.5×	1.4k 1.5×	1.0k 1.5×	187	4.9k
Peter Eu Australia	26	1.8k 0.8×	618 0.5×	989 0.9×	1.5k 1.6×	415 0.6×	55	3.1k
Hojjat Ahmadzadehfar Germany	42	3.2k 1.4×	1.7k 1.3×	2.4k 2.1×	2.7k 2.9×	1.1k 1.5×	201	5.5k
Stanislas Pauwels Belgium	29	1.3k 0.6×	2.1k 1.6×	1.8k 1.5×	427 0.5×	1.2k 1.8×	76	3.5k
Ghassan El‐Haddad United States	24	1.5k 0.7×	625 0.5×	1.1k 1.0×	1.7k 1.8×	373 0.5×	97	3.3k

Countries citing papers authored by Peter Bernhardt

Since Specialization

Citations

This map shows the geographic impact of Peter Bernhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Bernhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Bernhardt more than expected).

Fields of papers citing papers by Peter Bernhardt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Bernhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Bernhardt. The network helps show where Peter Bernhardt may publish in the future.

Co-authorship network of co-authors of Peter Bernhardt

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Bernhardt. A scholar is included among the top collaborators of Peter Bernhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Bernhardt. Peter Bernhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hallqvist, Andreas, et al.. (2025). ¹⁷⁷Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial. Journal of Nuclear Medicine. 66(5). 707–712. 7 indexed citations

Essen, Martijn van, et al.. (2024). Improvements of 177Lu SPECT images from sparsely acquired projections by reconstruction with deep-learning-generated synthetic projections. EJNMMI Physics. 11(1). 53–53. 2 indexed citations

Gustafsson, Johan, Daniel Roth, Jan Tennvall, et al.. (2024). Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [¹⁷⁷Lu]Lu-DOTATATE. Journal of Nuclear Medicine. 65(7). 1070–1075. 15 indexed citations

McDougall, Lisa, Andreas Bauman, Peter Bernhardt, et al.. (2024). Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study. Journal of Nuclear Medicine. 65(4). 573–579. 8 indexed citations

Svensson, Johanna, et al.. (2023). Specific Uptake in the Bone Marrow Causes High Absorbed Red Marrow Doses During [¹⁷⁷Lu]Lu-DOTATATE Treatment. Journal of Nuclear Medicine. 64(9). 1456–1462. 16 indexed citations

Tschan, Viviane J., Francesca Borgna, Martina Stirn, et al.. (2022). Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 49(11). 3639–3650. 28 indexed citations

Hallqvist, Andreas, et al.. (2021). Optimizing the Schedule of PARP Inhibitors in Combination with 177Lu-DOTATATE: A Dosimetry Rationale. Biomedicines. 9(11). 1570–1570. 9 indexed citations

Baum, Richard P., Aviral Singh, Harshad Kulkarni, et al.. (2021). First-in-Humans Application of ¹⁶¹Tb: A Feasibility Study Using ¹⁶¹Tb-DOTATOC. Journal of Nuclear Medicine. 62(10). 1391–1397. 59 indexed citations

Andersson, Jonas, Tufve Nyholm, Crister Ceberg, et al.. (2021). Artificial intelligence and the medical physics profession - A Swedish perspective. Physica Medica. 88. 218–225. 10 indexed citations

10.

Rydèn, Tobias, et al.. (2017). Segmentation of Whole-Body Images into Two Compartments in Model for Bone Marrow Dosimetry Increases the Correlation with Hematological Response in ¹⁷⁷ Lu-DOTATATE Treatments. Cancer Biotherapy and Radiopharmaceuticals. 32(9). 335–343. 7 indexed citations

11.

Wängberg, Bo, et al.. (2016). Radiation exposure of the spleen during 177Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume. EJNMMI Physics. 3(1). 15–15. 36 indexed citations

12.

Haller, Stephanie, Giovanni Pellegrini, Christiaan Vermeulen, et al.. (2016). Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate. EJNMMI Research. 6(1). 13–13. 51 indexed citations

13.

Uusijärvi, Helena, Nicolas Chouin, Peter Bernhardt, et al.. (2009). Comparison of Electron Dose-Point Kernels in Water Generated by the Monte Carlo Codes, PENELOPE, GEANT4, MCNPX, and ETRAN. Cancer Biotherapy and Radiopharmaceuticals. 24(4). 461–467. 35 indexed citations

14.

Uusijärvi, Helena, Peter Bernhardt, Thomas Ericsson, & Eva Forssell‐Aronsson. (2006). Dosimetric characterization of radionuclides for systemic tumor therapy: Influence of particle range, photon emission, and subcellular distribution. Medical Physics. 33(9). 3260–3269. 45 indexed citations

15.

Forssell‐Aronsson, Eva, Peter Bernhardt, Bo Wängberg, et al.. (2006). Aspects on Radionuclide Therapy in Malignant Pheochromocytomas. Annals of the New York Academy of Sciences. 1073(1). 498–504. 8 indexed citations

16.

Elgqvist, Jörgen, Peter Bernhardt, Ragnar Hultborn, et al.. (2005). Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.. PubMed. 46(3). 464–71. 43 indexed citations

17.

Bernhardt, Peter, et al.. (2005). Differences in Biodistribution Between ^99m Tc-Depreotide, ¹¹¹ In-DTPA-Octreotide, and ¹⁷⁷ Lu-DOTA-Tyr ³ -Octreotate in a Small Cell Lung Cancer Animal Model. Cancer Biotherapy and Radiopharmaceuticals. 20(2). 231–236. 25 indexed citations

18.

Forssell‐Aronsson, Eva, Peter Bernhardt, Ola Nilsson, et al.. (2004). Biodistribution data from 100 patients i.v. injected with¹¹¹in-DTPA-D-Phe¹-Octreotide. Acta Oncologica. 43(5). 436–442. 31 indexed citations

19.

Bernhardt, Peter, Ola Nilsson, Håkan Ahlman, et al.. (2003). Biodistribution and Dosimetry of ¹⁷⁷ Lu-Labeled [DOTA ⁰ ,Tyr ³ ]Octreotate in Male Nude Mice with Human Small Cell Lung Cancer. Cancer Biotherapy and Radiopharmaceuticals. 18(4). 593–599. 49 indexed citations

20.

Kölby, Lars, Peter Bernhardt, Håkan Ahlman, et al.. (2001). A Transplantable Human Carcinoid as Model for Somatostatin Receptor-Mediated and Amine Transporter-Mediated Radionuclide Uptake. American Journal Of Pathology. 158(2). 745–755. 91 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact